Hypertension Putting the Guidelines into Practice
|
|
- Zoe Allen
- 5 years ago
- Views:
Transcription
1 Hypertension 2018 Putting the Guidelines into Practice Ally P.H. Prebtani Professor of Medicine Internal Medicine, Endocrinology & Metabolism McMaster University Canada
2 Faculty: Metabolism, Faculty Disclosure Ally P. H. Prebtani, BScPhm, MD, FRCPC Professor of Medicine, Internal Medicine, Endocrinology & McMaster University Relationships with financial sponsors: Consultant: Servier Speakers Bureau: Servier Potential for conflict(s) of interest: Servier develops and benefits from the sale of products that might be discussed in this program. Disclosure of Investigational Use or Off-Label Use of Medical Devices, Products or Pharmaceuticals I will discuss or describe in my presentation at the meeting the investigational or unlabelled ( off-label ) use of a medical device, product, or pharmaceutical that is classified by Health Canada as investigational for the intended use.
3 Mitigating Potential Bias All the recommendations involving clinical medicine are based on evidence that is accepted within the profession. All scientific research referred to, reported, or used is in the support or justification of patient care. Recommendations conform to the generally accepted standards. Independent content validation. The presentation will mitigate potential bias by ensuring that data and recommendations are presented in a fair and balanced way. Potential bias will be mitigated by presenting a full range of products that can be used in this therapeutic area. Information of the history, development, funding, and the sponsoring organizations of the disclosure presented will be discussed.
4 Learning Objectives After active participation in the workshop, participants will be able to: 1. Be aware of what is new in hypertension and the guidelines 2. Accurately diagnose hypertension. 3. Formulate an approach to refractory hypertension 4. Decide when to refer
5 William Osler The young physician starts life with 20 drugs for each disease, and the old physician ends life with one drug for 20 diseases.
6 Benefits of lowering mild to moderate BP For every 10/5 mmhg lowering of BP 1,2,3 % reduction Stroke 35 40% Myocardial infarction (MI) 20 25% Heart failure (HF) 50% 1. MacMahon S, Peto R, Cutler J et al. Lancet 1990;335: Collins R, Peto R, MacMahon S et al. Lancet 1990;335: Staessen JA, Fagard R, Lutgarde T et al. Lancet 1997;350:
7
8 Hypertension Diagnostic Algorithm 1. Out of office assessment is the preferred means of hypertension Dx 2. Measurement using electronic (oscillometric) upper arm devices is preferred over auscultation ABPM = ambulatory blood pressure measurement AOBP = automated office blood pressure
9 Ways to Measure BP 1. AOBP (Automated Office) : Electronic (oscillometric) devices in upper arm HCP outside the room/area (mitigates white coat effect) Multiple readings Mean automatically calculated 2. ABPM 24hr (Ambulatory 24hr) 3. HBPM (Home) 9
10 Out-of-Office BP Measurements Out-of-office measurement identifies white coat hypertension and masked hypertension ABPM has better predictive ability than OBPM and is the recommended out-of-office measurement method HBPM has better predictive ability than OBPM and is recommended if ABPM is not tolerated, not readily available or due to patient preference ABPM = ambulatory blood pressure measurement HBPM = home BP measurement OBPM = office BP measurement
11 Out-of-Office BP Measurements are More Highly Correlated With BP-Related Risk LVH Albumin excretion ratio SBP OBP HBPM ABPM SBP DBP OBP HBPM ABPM DBP Indexes of hypertensive target organ damage Indexes of hypertensive target organ damage Mulè G, et al. J Cardiovasc Risk 2002;9:123-9.
12 Predictive value of AOBP AOBP predicts end-organ damage Systolic AOBP correlates with LVMI similarly to awake ABPM (Ambulatory) AOBP & 24-h ABPM have similar predictive ability for uacr AOBP is more strongly associated with cimt (compared to OBPM) More closely approximates ABPM than routine office BPs (mitigates white coat effect)1-3 Is more predictive of end organ damage (LVMI, proteinuria and cimt), similar to ABPM4-6 cimt: Carotid Intima Media Thickness LVMI: Left Ventricular Mass Index Campbell NRC, et al. J Hum Hypertens 2007;21:588-90; Andreadis EA, et al. Am J Hypertens 2011;24:661-6; Andreadis EA, et al. Am J Hypertens 2012;25: Beckett L, et al. BMC Cardiovasc Disord 2005;5:18; 2. Myers MG, et al. J Hypertens 2009;27:280-6;2 3. Myers MG, et al. BMJ 2011;342;d286;4. Campbell NRC, et al. J Hum Hypertens 2007;21:588-90; 5. Andreadis EA, et al. Am J Hypertens 2011;24:661-6; 6. Andreadis EA, et al. Am J Hypertens 2012;25:
13 Usual Office BP Threshold Values for Initiation of Pharmacological Treatment Population SBP DBP High Risk (SPRINT population) >130 NA Diabetes >130 >80 Moderate-to-high risk (TOD or CV risk factors)* >140 >90 Low risk (no TOD or CV risk factors) >160 >100 TOD = target organ damage *AOBP threshold >135/85 1 3
14 Recommended Office BP Treatment Targets Treatment consists of health behaviour ± pharmacological management * Target BP with AOBP < 135/85 1 4
15 New Thresholds/Targets for the High-Risk Patient Post-SPRINT Clinical or sub-clinical cardiovascular disease OR Chronic kidney disease (non-diabetic nephropathy, proteinuria <1 g/d, * estimated glomerular filtration rate ml/min/1.73m2) OR Estimated 10-year global cardiovascular risk 15% OR Age 75 years There was an increased risk of renal deterioration, potassium abnormalities and hypotension with intensified therapy Patients with one or more clinical indications should consent to intensive management Used AOBP * Four variable MDRD equation Framingham Risk Score, D'Agastino, Circulation 2008
16 New Thresholds/Targets for the High-Risk Patient Post-SPRINT: Who does this NOT apply to? Limited or No Evidence: Heart failure (EF <35%) or recent MI (within last 3 months) Indication for, but not currently receiving, a beta-blocker Institutionalized elderly Inconclusive Evidence: Diabetes mellitus Prior stroke egfr < 20 ml/min/1.73m 2 Contraindications: Patient unwilling or unable to adhere to multiple medications Standing SBP <110 mmhg Inability to measure SBP accurately Known secondary cause(s) of hypertension
17 CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 83 NUMBER 3 MARCH 2016
18 First Line Treatment of Adults with Systolic/Diastolic Hypertension Without Other Compelling Indications IF BP NOT CONTROLLED CONSIDER TARGET <135/85 mmhg (automated measurement method) INITIAL TREATMENT Nonadherence Secondary HTN Interfering drugs or lifestyle White coat effect Health behaviour management Thiazide/ thiazide-like* ACEI ARB Long-acting CCB Betablocker Single pill combination** * Longer-acting (thiazide-like) diuretics are preferred over shorter-acting (thiazide) diuretics BBs are not indicated as first line therapy for age 60 and above Renin angiotensin system (RAS) inhibitors are contraindicated in pregnancy and caution is required in prescribing to women of child bearing potential **Recommended SPC choices are those in which an ACE-I is combined with a CCB, an ARB with a CCB, or an ACE-I or ARB with a diuretic esp if target BP >20/10
19 Diuretic Type Meta-Analysis vs. Placebo Both types of diuretics reduced CV events, cerebrovascular events, & HF Only thiazide-like diuretics (chlorthalidone, indapamide) additionally reduced coronary events and all-cause mortality unlike HCTZ Event Thiazide-Type Thiazide-Like CV 0.67 ( ) 0.67 ( ) Coronary 0.81 ( ) 0.76 ( ) Cerebrovascular 0.52 ( ) 0.68 ( ) Heart Failure 0.36 ( ) 0.47 ( ) All-cause Mortality 0.86 ( ) 0.84 ( ) Olde Engberink RH. Hypertension 2015;65(5):
20 Mean change from baseline at week 12 Chlorthalidone > Effective vs HCTZ in BP Reduction 0 Ambulatory SBP Ambulatory DBP P= HCTZ (n=18) Chlorthalidone (n=16) -14 P<0.001 Kruskal-Wallis test used with Dunn s test for multiple comparisons; comparison between baseline and Wilcoxon signed rank test results. Mean 24h SBP was significantly lower for the chlorthalidone group than for the HCTZ group at week 4 ( vs mmhg, respectively, P=0.019) and week 12 ( vs mmhg, respectively, P=0.013). Intent-to-treat population. Pareek AK, et al. J Am Coll Cardiol 2016;67(4):379-89
21 Choice of Pharmacological Treatment Individualized treatment Compelling indications: Ischemic Heart Disease Recent ST Segment Elevation-MI or non-st Segment Elevation-MI Left Ventricular Systolic Dysfunction Stroke Left Ventricular Hypertrophy Non Diabetic Chronic Kidney Disease Renovascular Disease Diabetes Mellitus With Nephropathy Without Nephropathy Global Vascular Protection for Hypertensive Patients Statins if >/= additional CV risk factors? Aspirin once blood pressure is controlled
22 Evidence in Compelling Indications
23 Low Sodium
24 Impact of health behaviours on BP Intervention Diet and weight control (BMI < 25; WC < **) Systolic BP (mmhg) Diastolic BP (mmhg) Reduced salt/sodium intake < 2g/d Reduced alcohol intake (heavy drinkers) < 2 drinks/day DASH diet Physical activity (30-60 minutes 4-7 days/week) Relaxation therapies Multiple interventions Clinical Guideline : Methods, evidence and recommendations National Institute for Health and Clinical Excellence (NICE) May
25 Definition & Epidemiology Resistant HTN BP above target 3 optimally dosed Rx including thiazide or ACEI/ARB or DHP-CCB BP at target 4 or more drugs > CV Mortality & Morbidity (CHF, Stroke, CKI, MI) Due to HTN, Co-morbidities, EOD 20% of adults 8-12% primary care 11-21% specialized clinics Pseudo-resistance limits actual prevalence
26 Suboptimal therapy Not on diuretic Extracellular volume expansion Salt Poor compliance Combo pill, HBPM Secondary hypertension Primary hyperaldosteronism, NSAIDs, EtOH Office or "white coat" hypertension Pseudo-hypertension technique
27 How to Evaluate? r/o Pseudo-resistance White-coat 40% HBPM ABPM Technique Non-adherance Suboptimal regimen Look for secondary HTN 10% in tertiary care
28 Secondary HTN Endocrine Pheo, Cushing s, Primary Hyperaldosteronism Hypercalcemia, Thyroid Renal RAS, CKD Cardiac Coarctation OSA Drugs/Toxins
29 Meds/Toxins Padwal et al. CMAJ 2014
30 General Work-Up
31 Work-Up Secondary HTN Creatinine, Potassium TSH, Ca Sleep study Aldosterone/Renin? Imaging for RAS 24hr UFC 24hr urine metanephrines/catacholamines Echo prn
32 Effective Meds Modifications Optimal dosing & drugs Thiazide/Thiazide-like diuretics ACEI/ARB DHP-CCB Mineralocorticoid receptor antagonists (Spironolactone) Beta-blockers Non-DHP CCB (Diltiazem, Verapmil) Furosemide (loop) Volume excess GFR < 30-50mL/min Alpha-blockers Amiloride, DRI (Alikiseren), Clonidine, Methyldopa, Minoxidil, Hydralazine
33 Spironolactone (PATHWAY-2) Spiro 25-50mg/day vs placebo, bisoprolol, doxazosin Drug resistant HTN (A + C + D) RCT crossover trial BP < 135mmHg in 60% Williams B et al, Lancet, Sept 2015
34 Mechanisms Na retention Low renin ACTH dep Aldo hypersecretion Chronic stress via ACTH hypersecretion Gene mutations Zona Glomerulosa responsiveness Williams B et al, Lancet, Sept 2015
35 Approach Padwal et al. CMAJ 2014
36 Padwal et al. CMAJ 2014
37 Adherence improved by a multi-pronged approach Assess adherence at every visit Take pills on regular schedule with routine daily activity e.g. brushing teeth Simplify regimens using long-acting once-daily dosing Utilize fixed-dose combination pills Utilize unit-of-use packaging e.g. blister packaging Replacing with single pill combinations
38 Advantages of Single Pill Combinations (SPCs) SPC therapy is associated with better adherence vs. free combinations 1 A regimen featuring initial prescription of SPC leads to better BP control 2 Initial combination therapy is associated with risk of CV events than monotherapy 3,4 1. Sherrill B, et al. J Clin Hypertens 2011;13: ; 2. Feldman RD, et al. Hypertension 2009;53:646-53; 3. Corrao G, et al. Hypertension 2011;58:566-72; 4. Gradman AH, et al. Hypertension 2013;61(2):
39 SPC Combining an ACEI/ARB With CCB/Diuretic as First Line Rx 2 key studies establishing the utility of SPCs as first line: HOPE-3. N Engl J Med 2016;374(21): Pivotal study demonstrating the superiority of an SPC (ARB/diuretic) vs. Placebo ACCOMPLISH. N Engl J Med 2008;359(23): Demonstration of efficacy of ACEI/CCB SPC vs. active control
40 Other Strategies Bedtime dosing of one agent Combination therapy with different MOA Once daily long-acting agents Blister packaging Self-monitoring BP Education families and patient Multi-D RNs, RDs, pharmacists Base on compelling indications CHF, DM, MI/CAD, CKD, Stroke
41 When to refer to HTN specialist? Truly refractory Secondary cause of HTN Intolerance to many medications End organ damage requiring more specialized care
42 hypertension.ca For patients: Free access to the latest information and resources For professionals: Accredited 15.5 hour interdisciplinary training program Free monthly news updates, featured research and educational resources Become a member for special privileges and savings
43 Question 1 The SPRINT study included all patients but one of the following: a. Prior stroke b. egfr < 50ml/min c. Already on BP meds d. CAD/MI
44 Question 2 What method of BP monitoring is least accurate and least predictive of outcomes? a. Home automated (HBPM) b. Office automated (AOBP) c. 24hr ambulatory (ABPM) d. Office sphygamometer
45 Question 3 What is the most under-diagnosed cause of Secondary HTN? 1. Cushing s 2. Primary Hyperaldosteronism 3. Pheochromocytoma 4. Coarctation of the Aorta
46 Question 4 In a patient with Diabetes and Nephropathy, what would be your 1 st line therapy for HTN? 1. ACEI or ARB 2. Beta Blocker 3. Calcium Channel Blocker 4. Thiazide
47 Question 5 All of the following drugs can cause HTN except? 1. NSAIDs 2. OCP s 3. Sudafed 4. Codeine
48 Question 6 Beta blockers are 1 st line therapies in all of the following except? 1. Stable Angina 2. Diabetes Mellitus 3. CHF with LV dysfunction 4. Recent MI
49 Take Home Messages Move towards automated BP measurements AOBP Use of HBPM/ABPM Don t forget Lifestyle measures Global Vascular Health Lipids, smoking, Statins, DM Think about compelling indications Patient buy in for adherence Combo pills, once daily forms Aldosterone antagonists Consider target SBP < 120 for High Risk Patients SPRINT esp LV dysfunction If the patient is not at target, ask why? Ask about salt intake, EtOH, Adherance, OSA Proper BP technique Home BP monitoring/abp 2º HTN
50 Cases 1. 55yo man with HTN and LV dysfunction 2. 60yo woman with HTN, DM and proteinuria 3. 70yo man with HTN and stroke a week ago 4. 48yo man with recent MI, LV function normal, no DM 5. 39yo woman with new HTN and K 3.6, otherwise health 6. 49yo man office BP 145/92, otherwise healthy & no EOD 7. 65yo man CKD egfr 45, proteinuria; no DM or CVA
Hypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Disclosures Relationships with commercial interests: Grants/Research Support: Speakers Bureau/Honoraria: Consulting Fees: Data Safety and Monitoring:
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationHypertension Update. Faculty/Presenter Disclosure
Hypertension Update Who Gives a CHEP About Targets? Faculty/Presenter Disclosure Presenter: Raj Padwal Relationships that may introduce potential bias and/or conflict of interest: Grants/Research Support:
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationHypertension and Atrial Fibrillation
Hypertension and Atrial Fibrillation Sheldon Tobe MD, MScCH (HPTE), FRCPC, FACP, FASH Hypertension and Nephrology HSF/NOSM Chair in Aboriginal and Rural Health Research Professor in Medicine, University
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationWhat s New? Hypertension Canada Guidelines for the Management of Hypertension
What s New? 2017 Hypertension Canada Guidelines for the Management of Hypertension What s New? About This Booklet This booklet highlights key advancements and important, enduring aspects of the Hypertension
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice 2017-09-08 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any
More informationMasked Hypertension. Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre
Masked Hypertension Why Should We Care? Dr. Peter J. Lin Director Primary Care Initiatives - Canadian Heart Research Centre PRESENTER DISCLOSURE Faculty: Dr. Peter Lin Relationships with commercial interests:
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationAdult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
More informationHypertension Canada CHEP Guidelines for the Management of Hypertension. What s new in the treatment of hypertension? What s still really important?
Hypertension Canada CHEP Guidelines for the Management of Hypertension What s new in the treatment of hypertension? What s still really important? 1 Presenter Disclosure Relationships with commercial interests:
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationHypertension Update Background
Hypertension Update Background Overview Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Management Guideline Comparison
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationHypertension Update. Aaron J. Friedberg, MD
Hypertension Update Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Background Diagnosis Management Overview Guideline
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationManagement of Hypertension in Women
Management of Hypertension in Women Eliseo J. Pérez-Stable MD Professor of Medicine DGIM, Department of Medicine July 1, 2013 Declaration of full disclosure: No conflict of interest (I have never been
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More informationHypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations
Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations Gerald W. Smetana, M.D., MACP Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationDisclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1
Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationRESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University
RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationRESISTANT HYPERTENSION
RESISTANT HYPERTENSION John D. Bisognano, MD PhD Professor of Medicine / Cardiology President-Elect, American Society of Hypertension Director, Outpatient Cardiology University of Rochester RESISTANT HYPERTENSION
More informationNew Hypertension Guidelines. Kofi Osei, MD
New Hypertension Guidelines Kofi Osei, MD None Disclosures Objectives The new blood pressure definitions and cardiovascular risk The role to time and location in the diagnosis of hypertension Apply evidence-based
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationHypertension: Update
Hypertension: Update Meenakshi A Bhalla MD,FACC Associate Professor of Medicine Director Preventive Cardiology Advanced Heart Failure and Transplant Cardiology University of Kentucky Faculty Disclosure
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationHypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA
Hypertension Update 2016 AREEF ISHANI, MD MS CHIEF OF MEDICINE MINNEAPOLIS VA MEDICAL CENTER PROFESSOR OF MEDICINE UNIVERSITY OF MINNESOTA Case 1 What should be your BP goal for an elderly (> 75 yrs of
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More information2020 HYPERTENSION HIGHLIGHTS
2020 HYPERTENSION HIGHLIGHTS A Practical Guide informed by the Hypertension Canada Guidelines for the Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension BLOOD PRESSURE MEASUREMENT TECHNIQUE
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationHypertension 2015: Recent Evidence that Will Change Your Practice
Hypertension 2015: Recent Evidence that Will Change Your Practice Gerald W. Smetana, M.D. Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine Harvard Medical School
More informationPractical Aspects of Hypertension: Simple Strategies to Help You and Your Patients Meet Guideline Blood Pressure Targets
Practical Aspects of Hypertension: Simple Strategies to Help You and Your Patients Meet Guideline Blood Pressure Targets Robert J. Herman University of Calgary herman@ucalgary.ca Conflict of Interest Disclosure
More informationDEPARTMENT OF GENERAL MEDICINE WELCOMES
DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global
More informationHypertension Update. Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016
Mayo Clinic 90 th Annual Clinical Reviews November 2 nd and 16 th, 2016 Hypertension Update Vincent J. Canzanello, M.D. Consultant, Division of Nephrology and Hypertension Professor or Medicine College
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationWhat in the World is Functional Medicine?
What in the World is Functional Medicine? An Introduction to a Systems Based Approach of Chronic Disease Meneah R Haworth, FNP-C Disclosure v I am a student of the Institute for Functional Medicine. They
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationHow do we diagnose hypertension today? Presentation Subtitle
How do we diagnose hypertension today? Presentation Subtitle Renata Cífková Case 1 JM, a 64-year-old lady referred to our center because of undesirable effects of her antihypertensive medication Personal
More informationThe New Hypertension Guidelines
The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts
More informationPHASE Preventing Heart Attacks & Strokes Everyday
PHASE Preventing Heart Attacks & Strokes Everyday Welcome to the PHASE Learning Community! Joseph D. Young, MD Kaiser Permanente Northern California Jean Nudelman Kaiser Permanente Northern California
More informationWe are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.
Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More information2014 HYPERTENSION GUIDELINES
2014 HYPERTENSION GUIDELINES Eileen M. Twomey, Pharm.D., BCPS 1 Learning Objectives Describe specific blood pressure thresholds at which antihypertensive therapy should be initiated and blood pressure
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationThiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14
Thiazide or Thiazide Like? Choosing Wisely Academic Detailing Conference Digby Pines October 12-14 Disclosures Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance
More informationCOMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC
COMPLEX HYPERTENSION Anita Ralstin, FNP-BC Next Step Health Consultant, LLC Incidence Of Hypertension About 70 million American adults have high blood pressure. About 33% of the population Only 52% have
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationCKD & HT. Anne-Marie Angus
CKD & HT Anne-Marie Angus Hypertension definitions Persisting BP >140/90 and HBPM >135/85 Stage 1 >140/90 (HBPM >135/85) Stage 2 >160/100 (HBPM >150/90) Severe >180/100 White coat HT Why treat? A major
More informationHypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program
Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationHTN talk_l Davis_ /28/2018
1 2 GUIDELINES PUBLISHED AHEAD OF PRINT NOV 13, 2017 = SAME DAY AS PUBLIC PRESENTATION LESLIE L DAVIS, PHD, RN, ANP-BC, FPCNA, FAANP, FAHA The New Guidelines Have Been Published! Whelton PK, Carey RM,
More informationCreative blood pressure management: whys and the tricks
Creative blood pressure management: whys and the tricks Cynthia D. Caraballo-Hunt, MD Kaiser/OHSU Family Medicine Faculty Beaverton Medical Office NW Permanente, Portland, OR Objectives 1. Describe current
More informationHypertension. Most important public health problem in developed countries
Hypertension Strategy for Continued Success in Treatment for the 21st Century November 15, 2005 Arnold B. Meshkov, M.D. Associate Professor of Medicine Temple University School of Medicine Philadelphia,
More informationReframe the Paradigm of Hypertension treatment Focus on Diabetes
Reframe the Paradigm of Hypertension treatment Focus on Diabetes Paola Atallah, MD Lecturer of Clinical Medicine SGUMC EDL monthly meeting October 25,2016 Overview Physiopathology of hypertension Classification
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationHypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC
HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationManagement of Hypertension. Ahmed El Hawary MD Suez Canal University
Management of Hypertension Ahmed El Hawary MD Suez Canal University Minimal vs. Optimal Care Resources more than science affect type of care and level of management. what is possible (minimal care) and
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationJNC-8. (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines
JNC-8 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines Derrick Sorweide, DO Assistant Professor of Family Medicine,
More informationHypertension: 2016 Clinical Update
PHASE Safety Net Community Benefit Hypertension: 2016 Clinical Update Presented by: Joseph Young, MD Hypertension Clinical Lead Kaiser Permanente Northern California October 6, 2016 Dr. Joseph Young Hypertension
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationHypertension and the 2017 Guidelines Meeting the Targets in Small Groups. Lisa Ivy APRN
Hypertension and the 2017 Guidelines Meeting the Targets in Small Groups Lisa Ivy APRN The 2017 Guideline is an Update to JNC7 New information regarding BP related risk of CVD Ambulatory BP monitoring
More informationObjectives. JNC 7 Is Nice But What s Up With JNC 8? Why Do We Care? Hypertension Background: Prevalence
JNC 7 Is Nice But What s Up With JNC 8? 37 th Annual CAPA Conference October 4 th 2013 Ignacio de Artola, Jr. M.D. Assistant Professor of Clinical Family Medicine Medical Director, Primary Care Physician
More information